9. I confirm that the patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression. 10. I confirm the licensed dose and frequency of ibrutinib will be used. 11. What is the acquisition cost of the drug including VAT (if applicable)? £ per month: Commissioners will complete if cost not known as this will allow us to ensure budgets are allocated appropriately.
9. I confirm that the patient has had no prior treatment with idelalisib unless idelalisib has had to be stopped within 6 months of its start solely as a consequence of dose-limiting toxicity and in the clear absence of disease progression. 10. I confirm the licensed dose and frequency of ibrutinib will be used. 11. What is the acquisition cost of the drug including VAT (if applicable)? £ per month: Commissioners will complete if cost not known as this will allow us to ensure budgets are allocated appropriately.
IBR1_Ibrutinib_prevtreated_CLL_Nov16.docx